Management of Stage 3b CKD in a 70-Year-Old Patient
The next step is to confirm the diagnosis with repeat testing within 3 months, assess for albuminuria with a urine albumin-to-creatinine ratio (UACR), and evaluate for CKD complications including blood pressure control, electrolytes, anemia, and metabolic bone disease 1, 2.
Immediate Diagnostic Confirmation
With a creatinine of 127 µmol/L (approximately 1.4 mg/dL) and eGFR of 39 mL/min/1.73 m², this patient has Stage 3b CKD (eGFR 30-44 mL/min/1.73 m²) 3, 4. However, before proceeding with extensive management:
- Repeat creatinine and eGFR within 3 months to confirm chronicity, as CKD requires abnormalities persisting ≥3 months 4
- Obtain UACR on a spot urine sample (ideally early morning) - this is essential for risk stratification and should be done at least annually 1, 2
- Rule out acute kidney injury (AKI) by reviewing recent medications (NSAIDs, ACE inhibitors, ARBs, diuretics), volume status, and any precipitating factors 1, 5
Risk Stratification and Monitoring
The combination of eGFR and albuminuria determines both prognosis and monitoring frequency 6, 2:
- If UACR <30 mg/g: Moderate risk - monitor every 6 months
- If UACR 30-299 mg/g: High risk - monitor every 4-6 months
- If UACR ≥300 mg/g: Very high risk - monitor every 3-4 months
Evaluate for CKD Complications
At eGFR <60 mL/min/1.73 m², complications become prevalent and require systematic evaluation 1, 5:
Laboratory assessment every 6-12 months for Stage 3 CKD:
- Serum electrolytes (sodium, potassium, bicarbonate) - assess for metabolic acidosis and hyperkalemia
- Complete blood count - screen for anemia (common when eGFR <60)
- Calcium, phosphate, PTH, vitamin D - evaluate for metabolic bone disease
- Blood pressure at every visit - target <130/80 mmHg 7
Medication Review and Nephrotoxin Avoidance
Critical action at this eGFR level 1, 5:
- Verify all medication doses are appropriate for eGFR 30-44 mL/min/1.73 m²
- Discontinue or minimize nephrotoxins: NSAIDs, iodinated contrast (use with caution only when necessary)
- Monitor potassium if patient is on ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists
- Do NOT discontinue ACE inhibitors/ARBs for creatinine increases <30% from baseline in absence of volume depletion 1, 5
Nephrology Referral Considerations
Referral to nephrology is recommended when eGFR <30 mL/min/1.73 m² 7, 4, 7. At eGFR 39, formal referral may not be immediately necessary if:
- The eGFR is stable over time
- The diagnosis is clear (e.g., age-related decline, hypertension, diabetes)
- No concerning features are present
However, refer NOW if any of the following exist 7:
- Abrupt sustained decline in eGFR >20% after excluding reversible causes
- UACR ≥300 mg/g (≥30 mg/mmol) or protein excretion >1 g/day
- Hypertension refractory to ≥4 antihypertensive agents
- Persistent hyperkalemia
- Urinary red blood cell casts or hematuria >20 RBCs/HPF
- Hereditary kidney disease suspected
Important Caveats for Age 70
In elderly patients, eGFR equations may underestimate actual kidney function 8, 9, 10. The BIS1 equation is more accurate than CKD-EPI in patients >70 years 8. Additionally:
- Age-related GFR decline (approximately 1 mL/min/year after age 40) is physiological but still requires appropriate management 10
- Sarcopenia and low muscle mass can lead to falsely reassuring creatinine values 11
- Consider cystatin C-based equations for more accurate assessment in elderly patients with suspected sarcopenia 11
Primary Care Management Strategy
For stable Stage 3b CKD without concerning features, primary care management includes 4, 7:
- Cardiovascular risk reduction (most patients with Stage 3 CKD die from cardiovascular causes, not progression to ESRD) 7
- Blood pressure control to <130/80 mmHg
- ACE inhibitor or ARB if hypertension or albuminuria present (use maximum tolerated doses) 3, 1
- Avoid protein restriction unless specifically indicated 7
- Annual monitoring of eGFR and UACR minimum
The key is distinguishing between stable, age-appropriate kidney function decline versus progressive CKD requiring specialist intervention.